Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates.

Szczegóły

Tytuł:: Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates.
Autorzy:: Leroux S; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Neonatal Intensive Care Unit, University Hospital Rennes, Rennes, France.
van den Anker JN; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Division of Clinical Pharmacology, Children's National Health System, Washington, DC, USA.
Smits A; Neonatal Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.
Pfister M; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Certara LP, Princeton, NJ, USA.
Allegaert K; Department of Development and Regeneration, KU Leuven, Leuven, Belgium.; Department of Pediatrics, Division of Neonatology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Źródło:: British journal of clinical pharmacology [Br J Clin Pharmacol] 2019 May; Vol. 85 (5), pp. 865-867. Date of Electronic Publication: 2019 Mar 04.
Typ publikacji:: Editorial
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: London, Macmillan Journals Ltd.
MeSH Terms:: Drug Dosage Calculations*
Anti-Bacterial Agents/*administration & dosage
Bacteremia/*drug therapy
Staphylococcal Infections/*drug therapy
Vancomycin/*administration & dosage
Adult ; Age Factors ; Anti-Bacterial Agents/pharmacokinetics ; Area Under Curve ; Bacteremia/microbiology ; Cohort Studies ; Computer Simulation ; Humans ; Infant, Extremely Low Birth Weight ; Infant, Extremely Premature ; Infant, Newborn ; Microbial Sensitivity Tests ; Models, Biological ; Proof of Concept Study ; Protein Binding ; Staphylococcal Infections/microbiology ; Staphylococcus/drug effects ; Vancomycin/pharmacokinetics
References:: Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1503-1510. (PMID: 29770901)
Semin Fetal Neonatal Med. 2013 Feb;18(1):28-34. (PMID: 23137927)
Br J Clin Pharmacol. 2013 Apr;75(4):1068-80. (PMID: 23148919)
BMC Pediatr. 2016 Dec 8;16(1):206. (PMID: 27931193)
Ther Drug Monit. 2007 Jun;29(3):284-91. (PMID: 17529884)
J Antimicrob Chemother. 2019 Aug 1;74(8):2128-2138. (PMID: 31049551)
Br J Clin Pharmacol. 2019 May;85(5):865-867. (PMID: 30834552)
Br J Clin Pharmacol. 2013 Jul;76(1):58-64. (PMID: 23210694)
Ther Drug Monit. 2016 Jun;38(3):419-20. (PMID: 27172382)
Clin Pharmacokinet. 2004;43(13):925-42. (PMID: 15509186)
Substance Nomenclature:: 0 (Anti-Bacterial Agents)
6Q205EH1VU (Vancomycin)
Entry Date(s):: Date Created: 20190306 Date Completed: 20200513 Latest Revision: 20231011
Update Code:: 20240105
PubMed Central ID:: PMC6475736
DOI:: 10.1111/bcp.13899
PMID:: 30834552
: Opinia redakcyjna

Full Text Finder

Informacja